Articles by Louis Garguilo

  1. Outsourcing From A To ZZ Biotech 3/1/2022

    Kent Pryor, CEO of ZZ Biotech, explains how he’s approached his single-handed “CEO As Outsourcer” role and provides advice to professionals of all positions in any biopharma organization.

  2. Defending Your Supply Chains From “Foreign Suppliers” 1/13/2022

    In “defense” of the integrity of your (offshore and onshore) drug development and manufacturing outsourcing, and during this year 3 CE (Covid Era): Considering suppliers as separate and somewhat removed entities – putting them at a distance – might be what it takes to subsequently bring you even closer to reliable partnerships. 

  3. These Professionals Are Creating Our Outsourcing Future 12/1/2021

    While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.

  4. Should You Build Where You Buy? A Rarely Discussed Model For Biopharma 9/23/2021

    You are an emerging biopharma outsourcing to a trusted CDMO that has selected its location wisely – an important factor in your selecting it. Now you’ve determined to establish some of your own development or manufacturing facilities. Would it be beneficial to build close to your CDMO?

  5. Not Particularly For A Pandemic, But The Supply Chain Was Ready 8/18/2021

    A discussion on lessons learned from the pandemic featured Remo Colarusso, Vice President, Janssen Supply Chain, Johnson & Johnson, and Ken Kent, Senior Vice President, Chemical Development and Manufacturing Operations, Gilead Sciences, at a recent DCAT Virtual Week event.

  6. Leaders Have An Appetite For Adaptability When Outsourcing 6/23/2021

    In part one - "Five Maxims For Outsourcing Success" - we tackled Lisa Wyman's first three of five tenets to better outsource by. Here we explore her belief that leveraging capabilities and capacities of CDMOs is predicated on an appetite for adaptability and flexibility, and that is exhibited as a quality of leadership.

  7. An All-Canada COVID-19 Vaccine Solution 6/1/2021

    The story of how Providence Therapeutics, a Calgary, Ontario-based, emerging mRNA biopharma, came to achieve such notoriety is an interesting one that includes a pivot from its core therapeutic focus, the hiring of an American as company president, and the creation of a CDMO.

  8. Ensysce Biosciences CEO Talks SPAC 5/18/2021

    Ensysce Biosciences CEO Lynn Kirkpatrick knows every organization is different, but believes any CEO of a biotech today might consider going the special purpose acquisition company (SPAC) route to financially fuel the organization. Here’s how and why she and Ensysce decided to move forward.

  9. SPACs, Opioids, and COVID: Ensysce Biosciences Making “Virtual” History 5/10/2021

    If Ensysce Biosciences were a ball of yarn, we’d be unwinding it for hundreds of miles from its location in La Jolla, California. We’d unravel solid oral dose programs – new opioids and a COVID treatment, an all-outsourced model, and now one of the first biotechs to go public via a SPAC (special purpose acquisition company).

  10. Should Your CDMO Become A 503B? 4/1/2021

    A reader pulled me down an Alice-In-Wonderland rabbit hole. I’m glad she did, though. If you read the headline above and thought, “What exactly is a 503B?” you’ll be glad, too.